James,
From the line ... here's the implied math ...
None of that was in the article ... that was
MY INTERPRETATION of what the numbers logically
mean.
All the article said was $100,000,000 mil. in revenue
in '99 , $350 a shot in Canada , $30 (of the $350)
goes to Biomatrix, and some competing company was selling
a competing product for $495.
I RAN WITH an assumption that Biomatrix gets $30 a shot.
If revenues are $100,000,000 mil then you can work back
to a people count, and see what that people count is vs.
the whole arthritis population of 16,000,000.
The math worked out that $100,000,000 to Biomatrix @ $30
a shot ASSUMES a 3.5% acceptance by the total potential
user group.
Sorry if I confused you. And I hope this follow-up
doesn't make it worse.
In any event, the end of the 4th qt. will be somewhat
revealing in terms of we will SEE how much PIPELINE
product AHP ordered from BIOX.
I warn you though, the real story is China.
Regards,
John McCarthy |
